An update on primary drug therapies for Alzheimer disease

Archives of Neurology

Volumn 54, Issue 11, 1997, Pages 1406-1409

  Knopman, David S ^{a,c,d,e,f,g,h,i}   Morris, John C ^{b,c,e,f,g,j,k,l,m,n,o}  

^a UNIVERSITY OF MINNESOTA   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c PFIZER INC   (United States)

^d Athena Neurosciences Inc   (United States)

^e EISAI INC   (United States)

^f NOVARTIS PHARMA AG   (Switzerland)

^g BAYER CORPORATION   (United States)

^h WYETH AYERST RESEARCH   (United States)

ⁱ FOREST RESEARCH INSTITUTE   (United States)

^j ELI LILLY AND COMPANY   (United States)

^k JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^l HOFFMANN LA ROCHE INC   (United States)

^m SANOFI   (France)

ⁿ Smith Kline   (United States)

^o GD Searle Co   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; CHOLINESTERASE INHIBITOR; SELEGILINE;

AGITATION; ALZHEIMER DISEASE; ANXIETY; CAREGIVER; COGNITIVE DEFECT; DEPRESSION; MEMORY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SLEEP DISORDER; TREATMENT OUTCOME;

EID: 0030730113     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.1997.00550230073020     Document Type: Review

References (27)

1. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI, A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease: the Tacrine Study Group. JAMA. 1994;271:985-991.
2. Rogers SL, Friedhoff LT, for the Donepezil Study Group. The efficacy and safety of donepezil in patients with mild to moderate Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. Dementia. 1996;7:293-303.
3. Rogers SL, Doody R, Mohs R, Friedhoff LT. E2020 produces both clinical global and cognitive test improvement in patients with mild to moderately severe Alzheimer's disease: results of a 30-week phase III trial. Neurology. 1996;46(suppl): A217.
4. Anand R, Enz A. Clinical confirmation of preclinical attributes: the ANENA program. Neurobiol Aging. 1996;17(suppl 4s):S87.
5. Morris J, Cyrus P, Orazem J, Mas J, Bieber F, Gulanski B. Effects of metrifonate on the cognitive, global, and behavorial function of Alzheimer's disease patients: results of a randomized, double-blind, placebo-controlled study. Neurology. 1997;48:1730. Abstract.
6. Wilcock G, Wilkinson D. Galanthamine hydrobromide: interim results of a group comparative, placebo controlled study of efficacy and safety in patients with a diagnosis of senile dementia of the Alzheimer type. Neurobiol Aging. 1996;17 (suppl 4S):S144.
7. Thal LJ, Schwartz G, Sano M, et al, for the Physostigmine Study Group. A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Neurology. 1996;47:1389-1395.
8. Knopman D, Schneider L, Davis K, et al. Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality. Neurology. 1996;47:166-177.
9. Kaufer DI, Cummings JL, Christine D. Effects of tacrine on behavioral symptoms in Alzheimer's disease: an open label study. J Geriatr Psychiatry Neurol. 1996;9:1-6.
10. Raskind MA, Sadowsky CH, Sigmund WR, Beitler PJ, Auster SB. Effect of tacrine on language, praxis and noncognitive behavioral problems in Alzheimer disease. Arch Neurol. 1997;54:836-840.
11. Bodick N, Offen W, Levey AI, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol. 1997;54:465-473.
12. Kumar R, on behalf of the Smith Kline Beecham Alzheimer's Disease Study Group. Efficacy and safety of SB202026 as a symptomatic treatment for Alzheimer's disease. Ann Neurol. 1996;40:504. Abstract.
13. Asthana S, Craft S, Baker LD, et al. Transdermal estrogen improves memory in women with Alzheimer's disease. Soc Neurosci Abstracts. 1996;22:200.
14. Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology. 1993;43:1609-1611.
15. Aisen PS, Davis KL. The search for disease-modifying treatment for Alzheimer's disease. Neurology. 1997;48(suppl 6):S35-S41.
16. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease: the Alzheimer's Disease Cooperative Study. N Engl J Med. 1997;336:1216-1222.
17. Morris JC. Clinical dementia rating (CDR): current version and scoring rules. Neurology. 1993;43:2412-2414.
18. Perrig WJ, Perrig P, Stahelin HB. The relation between antioxidants and memory performance in the old and very old. J Am Geriatr Soc. 1997;45:718-724.
19. Thal LJ, Carta A, Clarke WR, et al. A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease. Neurology. 1996;47: 705-711.
20. Bowen DM, Francis PT, Chessell IP, et al. Alzheimer's disease: is the improvement of cholinergic transmission the correct strategy? In: Cutler NR, Gottfries CG, Siegfried K, eds. Alzheimer's Disease: Clinical and Treatment Perspectives. New York, NY; John Wiley & Sons Inc; 1995:89-116.
21. Lynch G, Kessler M, Rogers G, Ambros-Ingerson J, Granger R, Schehr RS. Psychological effects of a drug that facilitates brain APMA receptors. Int Clin Psychopharmacol. 1996;11:13-19.
22. Selkoe D. Amyloid β-protein and the genetics of Alzheimer's disease. J Biol Chem. 1996;271:18295-18298.
23. Strittmatter WJ, Weisgraber KH, Goedert M, et al. Hypothesis: micortubule instability and paired helical filament formation in the Alzheimer disease brain are related to apolopoprotein E genotype. Exp Neurol. 1994;125:163-171.
24. Yamada K, Nitta A, Hasegawa T, et al. Orally active NGF stimulators: potential therapeutic agents in Alzheimer's disease. Behav Brain Res. 1997;83:117-122.
25. Thal LJ. Potential prevention strategies for Alzheimer disease. Alzheimer Dis Assoc Disord. 1996;10(suppl 1):6-8.
26. Thompson TL, Filley CM, Mitchell WD, et al. Lack of efficacy of hydergine in patients with Alzheimer's disease. N Engl J Med. 1990;323:445-448.
27. Little A, Levy R, Chuaqui-Kidd P, Hand D. A double-blind, placebo-controlled trial of high-dose lecithin in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 1985; 48:736-742.